Abstract: The present invention discloses the use of Eletriptan Hydrobromide in the treatment of spinal cord injury and improvement of the locomotive function. Despite the major efforts done in attempting to improve the limited recovery upon injury, only a multi-target combinatorial therapeutic approach should be effective for the complexity of spinal cord injury nature. Taking advantage of a larval zebrafish drug discovery platform it is identified herein that Eletriptan Hbr has locomotor recovery properties in a pro-regenerative model and it has been confirmed to have conservative effect on a rodent (pro-fibrotic) contusion model. This approach allowed to identify a promising new therapeutic indication for Eletriptan Hbr, which associated with a combinatorial therapeutic strategy and innovative engineering approaches, shows great potential for spinal cord injury recovery.